Jeff Yass’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.1M Buy
71,351
+45,261
+173% +$867K ﹤0.01% 7708
2026
Q2
$475K Sell
26,090
-21,287
-45% -$316K ﹤0.01% 10037
2026
Q1
$673K Buy
47,377
+7,555
+19% +$97.1K ﹤0.01% 8895
2025
Q4
$412K Buy
39,822
+4,202
+12% +$37.9K ﹤0.01% 9235
2025
Q3
$211K Sell
35,620
-94,298
-73% -$691K ﹤0.01% 10879
2025
Q2
$978K Buy
129,918
+50,480
+64% +$406K ﹤0.01% 7491
2025
Q1
$601K Buy
79,438
+43,702
+122% +$419K ﹤0.01% 8498
2024
Q4
$435K Buy
35,736
+2,155
+6% +$31K ﹤0.01% 9020
2024
Q3
$562K Buy
33,581
+18,095
+117% +$321K ﹤0.01% 8183
2024
Q2
$270K Sell
15,486
-19,129
-55% -$407K ﹤0.01% 9682
2024
Q1
$590K Buy
34,615
+14,651
+73% +$226K ﹤0.01% 8106
2023
Q4
$203K Buy
19,964
+7,017
+54% +$62.2K ﹤0.01% 10651
2023
Q3
$117K Sell
12,947
-9,568
-42% -$100K ﹤0.01% 10786
2023
Q2
$242K Buy
22,515
+1,287
+6% +$13.7K ﹤0.01% 9873
2023
Q1
$217K Buy
+21,228
New +$234K ﹤0.01% 10425
2022
Q4
– Sell
-19,775
Closed -$254K – 12513
2022
Q3
$254K Buy
+19,775
New +$266K ﹤0.01% 10234
2022
Q2
– Sell
-15,182
Closed -$159K – 12972
2022
Q1
$159K Sell
15,182
-13,064
-46% -$177K ﹤0.01% 11501
2021
Q4
$436K Buy
+28,246
New +$563K ﹤0.01% 9547

Other funds holding CGEM

Jeff Yass's CGEM Position: Q3 2026 in Review

Jeff Yass increased its Cullinan Therapeutics (CGEM) stake by 173% in Q3 2026, buying an estimated $867K and bringing the position to 71,351 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #7708.

Jeff Yass first reported a position in CGEM in Q4 2021 and has held it in 18 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Jeff Yass held 71,351 shares of Cullinan Therapeutics worth $1.1M as of Q3 2026.
  • Jeff Yass bought 45,261 Cullinan Therapeutics shares in Q3 2026, an estimated $867K.
  • Cullinan Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #7708 holding.
  • Jeff Yass first reported a position in Cullinan Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.